Immunology & Inflammation
Recent research highlights the potential of psychedelics, particularly psilocybin and MDMA, in modulating immune responses and inflammation, shedding light on their therapeutic implications for mood disorders and other immune-related conditions. Studies are beginning to uncover the mechanisms through which these compounds exert anti-inflammatory effects and promote neuroplasticity, particularly in the context of major depressive disorder (MDD).
Key Insights
- 1
Emerging studies indicate psilocybin may exert anti-inflammatory effects by modulating immune responses and cytokine levels.
- 2
MDMA has shown promise not only in treating PTSD but also in tackling immunological aspects related to stress and depression.
- 3
Psychedelics could fundamentally alter the treatment framework, shifting from purely symptomatic treatment to addressing underlying inflammatory processes.
What is Immunology & Inflammation?
Inflammation is a critical component of various pathological conditions, including autoimmune diseases, neurodegenerative disorders, and mood disorders like major depressive disorder (MDD).
In MDD, chronic systemic inflammation can exacerbate symptoms and impede recovery, suggesting a bidirectional relationship between immune dysregulation and mood disorders.
Pathophysiological mechanisms involve pro-inflammatory cytokines, which can influence neurotransmitter metabolism and neuronal health, leading to disturbances in mood and behaviour.
Symptomatic manifestations may include persistent sadness, anhedonia, cognitive dysfunction, and fatigue, often accompanied by somatic complaints which might be linked to underlying inflammation.
Current Treatments
Standard-of-care treatments for MDD often include a combination of antidepressants (SSRIs, SNRIs) and psychotherapy, with some patients benefitting from anti-inflammatory agents as adjunct therapies. However, these options are limited in efficacy and not universally effective.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Immunology & Inflammation.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Psilocybin has robust evidence supporting its immunomodulatory effects, particularly in depressive disorders. | Large | High | Consistent |
| MDMA MDMA shows promise in improving emotional well-being and possibly influencing inflammatory markers. | Medium | Moderate | Consistent |
| LSD Research on LSD's effects on inflammation is limited and yields mixed results. | Small | Low | Inconsistent |
Psilocybin and Immunology & Inflammation
Psilocybin has been shown to possess significant anti-inflammatory properties, which may play a crucial role in its therapeutic potential for treating major depressive disorder. The compound appears to modulate inflammatory cytokines, thereby potentially improving mood states and cognitive function through neuroplastic changes facilitated by the reduction of neuroinflammation.
MDMA and Immunology & Inflammation
MDMA's unique pharmacological profile not only impacts serotonin and dopamine pathways but also suggests a potential link to inflammatory processes in the brain. Research indicates that MDMA can enhance pro-social behaviour and reduce fear response, which in the context of its anti-inflammatory effects may facilitate emotional healing in patients suffering from trauma-related disorders.
Clinical Outlook
The future of psychedelic treatment appears promising, particularly for conditions linked with inflammation and immune dysregulation. Ongoing clinical trials are likely to confirm the therapeutic efficacy of compounds like psilocybin and MDMA, paving the way for new strategies that integrate psychopharmacology with immunology to treat mood disorders more effectively.
Industrial Landscape
Key players in this arena include non-profits and research organisations such as MAPS (Multidisciplinary Association for Psychedelic Studies), John Hopkins University, and various biotech companies focused on psychedelic compounds and mental health therapies.
Quick Indicators
Organisations
Search →Restart Life Sciences
Canadian biotech (formerly Nova Mentis Life Science, renamed November 2024) developing psilocybin therapy for Fragile X Syndrome and autism spectrum disorder. Lead candidate NM-1001 received Health Canada authorisation for a Phase IIA clinical trial, making it one of the few psilocybin programmes targeting neurodevelopmental conditions.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Imperial College London
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
University of Ottowa
The University of Ottawa launched a groundbreaking one-year MA in Psychedelics and Consciousness Studies in 2024, jointly offered by the Faculty of Social Sciences and Faculty of Arts under co-directors Dr. Monnica Williams and Dr. Anne Vallely. The program builds on earlier microprograms in Psychedelic Science and Psychedelics & Spirituality Studies established since 2020, training licensed professionals, clergy, and researchers in therapeutic, spiritual, and academic dimensions of psychedelics.
King's College London
The Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.
Johns Hopkins University
The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
Yale University
In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
Oregon Health & Science University
Researchers at the Social Neuroscience and Psychotherapy (SNAP) Lab at OHSU are investigating the therapeutic potential of psychedelics. Assistant Professor of Psychiatry, Dr Chris Stauffer, is the current director of the lab. SNAP Lab aims to maximize the benefits of therapeutic alliance and psychotherapy through the adjunct use of social psychopharmacology, such as oxytocin, MDMA, and psilocybin. Dr Stauffer led a research team from OHSU in a clinical trial exploring the effects of psilocybin in methamphetamine use disorder. With Oregon becoming the first state to legalize psilocybin-assisted therapy, more research is taking place at OHSU.
Federal University of São Paulo (UNIFESP)
The Federal University of São Paulo (UNIFESP) is a public federal research university based in the state of São Paulo, Brazil, with multiple campuses and a strong reputation in health sciences and related programs.
Federal University of Rio Grande do Norte (UFRN)
Federal University of Rio Grande do Norte is a public research university in Brazil with active neuroscience and mental health research programmes, including work linked to psychedelic science through affiliated institutes.
People
Search →Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Michiel Van Elk
Associate Professor of Cognitive Psychology at Leiden University
Michiel van Elk is a prominent psychedelic science researcher known for rigorous, skeptical work on psilocybin, microdosing, expectancy effects, and the psychological mechanisms and risks of psychedelic experiences.
Joshua Di Vincenzo
MSc researcher / clinical research staff member at the University Health Network and University of Toronto
He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.
Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Bing Cao
PhD researcher at the Key Laboratory of Cognition and Personality, Faculty of Psychology, Southwest University
He is a recurring coauthor on multiple ketamine and psychedelic-adjacent systematic reviews and mechanistic studies, making him a visible contributor to contemporary rapid-acting antidepressant research.
Marcelo Falchi
Psychiatrist, Professor of Medicine at the Federal University of Rio Grande do Norte (UFRN), and Medical Director at the Center for Advanced Psychedelic Medicine (CAMP)
He is a Brazilian psychiatrist and psychedelic-science researcher involved in pioneering LSD and DMT clinical studies, including work on cognition, creativity, language, and inhaled DMT safety.
Mark Andrew Frye
Chair, Department of Psychiatry and Psychology, Mayo Clinic (Rochester, Minnesota)
He is a leading mood-disorders psychiatrist whose work has helped shape the clinical evidence base and consensus guidance for ketamine in depression.
Michael Grunebaum
Associate Professor of Psychiatry at Columbia University Irving Medical Center; Research Psychiatrist at the New York State Psychiatric Institute
He is a leading ketamine and suicidality researcher whose clinical trials and meta-analytic work helped shape rapid-acting antidepressant research in psychiatry.
Erwin Krediet
Psychologist and psychedelic researcher at ARQ National Psychotrauma Centre; PhD researcher at Leiden University Medical Center
He is a Dutch psychedelic researcher contributing to clinical studies and educational work on psychedelics, including MDMA-assisted psychotherapy for PTSD and LSD/psilocybin studies.
David Olson
TBD
TBD
Peter Hendricks
Professor of Health Behaviour and Psychedelic Research
Noted for rigorous population‑level epidemiological analyses elucidating associations between classic psychedelic use and mental and physical health outcomes, and for advancing research on microdosing and adverse psychological responses.
Connected Evidence
The latest clinical data and verified academic findings associated with Immunology & Inflammation.